Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2019

View Archived Issues

PARP degradation joins trapping, inhibition

Tau spreads quickly but kills slowly

HLX-11 receives IND application acceptance notification from NMPA

Cartesian initiates phase I/II study of its lead CAR-T candidate, Descartes-08

eFFECTOR Therapeutics initiates early clinical study of zotatifin in advanced solid tumors

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Initiation of phase Ib study of mavorixafor in severe congenital neutropenia

Regeneron provides updates on phase III development program of Libtayo in NSCLC

Daiichi Sankyo presents in vitro and in vivo data for DS-1039

NXP-031 leads to significant improvement of motor deficit in MPTP-induced mouse model of PD

Investigators design mouse model of dwarfism with PCSK1 mutation

EOLO-42016 shows promise in model of inherited ALS

Enzyme-replacement gene therapy encoding glucocerebrosidase attenuates PD phenotype

First phase I data presented for influenza vaccine OVX-836

Small molecules clear mutant Huntingtin protein

Tempest Therapeutics patents prostanoid EP2 and EP4 receptor antagonists

Incyte patent describes MAP4K1 inhibitors

TNBG-5602 induces lipid accumulation and antiproliferation in liver cancer cells through PPARgamma

Ark Biosciences reports topline proof-of-concept data for ziresovir in RSV

HitGen identifies new NTRK1 inhibitors

ATM and DNA-PK kinase inhibitors revealed in XRad Therapeutics patent

Shenzhen Targetrx Biotechnology patent details new tyrosine kinase inhibitors

4D reports preliminary phase I/II data on MRx-0518 with pembrolizumab in advanced malignancies

Dystrogen reports cardioprotective effects of DEC cells in Duchenne muscular dystrophy

BerGenBio reports updated phase II data on bemcentinib in advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...